Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 792-795, 2012.
Artigo
em Chinês
| WPRIM
| ID: wpr-263301
ABSTRACT
The effects of conventional treatment for myelodysplastic syndrome (MDS) are not remarkable to date, while only a minority of patients was eligible for allogeneic stem cell transplantation. As epigenetics plays a significant role during the occurrence and development of MDS, and histone deacetylase inhibitors (HDACI), a class of gene expression modulating drugs, are currently being developed for therapy of several types of solid tumor, more attention is paying to HDACI as potential therapy of MDS. This review summarizes briefly the rationale for HDACI use in MDS, the common mechanism of HDACI, the present state of the clinical efficiency, and future development in this field.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Síndromes Mielodisplásicas
/
Usos Terapêuticos
/
Epigênese Genética
/
Tratamento Farmacológico
/
Inibidores de Histona Desacetilases
/
Genética
Limite:
Humanos
Idioma:
Chinês
Revista:
Journal of Experimental Hematology
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS